AM9405

peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist

Also Known As:

(2-(2,6-dihydroxy-4-(2-methyloctan-2-yl)phenyl)-1,3-dimethyl-1H-benzo(d)imidazol-3-ium bromide; GAT379

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - AM9405: 2

Experts

1.	Binienda, Agata: 2 articles (11/2019 - 10/2018)
2.	Fichna, Jakub: 2 articles (11/2019 - 10/2018)
3.	Makriyannis, Alexandros: 2 articles (11/2019 - 10/2018)
4.	Salaga, Maciej: 2 articles (11/2019 - 10/2018)
5.	Storr, Martin: 2 articles (11/2019 - 10/2018)
6.	Thakur, Ganesh A: 2 articles (11/2019 - 10/2018)
7.	Tichkule, Ritesh B: 2 articles (11/2019 - 10/2018)

Related Diseases

1.	Abdominal Pain (Pain, Abdominal) 11/05/2019 - "Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. " 10/05/2018 - "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome." 10/05/2018 - "In the present study, we used mouse models of diarrhea, hypermotility, and abdominal pain to examine whether a novel synthetic CB1 receptor agonist AM9405 [(2-(2,6-dihydroxy-4-(2-methyloctan-2-yl)phenyl)-1,3-dimethyl-1H-benzo[d]imidazol-3-ium bromide); also known as GAT379] exhibits effects of potential therapeutic relevance. "
2.	Diarrhea 10/05/2018 - "Moreover, AM9405 reversed hypermotility and reduced pain in mouse models mimicking symptoms of functional GI disorders, such as stress-induced diarrhea and writhing test. " 10/05/2018 - "In the present study, we used mouse models of diarrhea, hypermotility, and abdominal pain to examine whether a novel synthetic CB1 receptor agonist AM9405 [(2-(2,6-dihydroxy-4-(2-methyloctan-2-yl)phenyl)-1,3-dimethyl-1H-benzo[d]imidazol-3-ium bromide); also known as GAT379] exhibits effects of potential therapeutic relevance. "
3.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 11/05/2019 - "Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. " 10/05/2018 - "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome."
4.	Pain (Aches) 10/05/2018 - "Moreover, AM9405 reversed hypermotility and reduced pain in mouse models mimicking symptoms of functional GI disorders, such as stress-induced diarrhea and writhing test. "

Related Drugs and Biologics

1.	AM9405
2.	CB1 Cannabinoid Receptor (CB1 Receptor)
3.	Serotonin (5 Hydroxytryptamine)
4.	Cannabinoids